Overview
News
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$3.3M
62 rounds on record
Latest round
$3.3M
Venture round · Jun 2024 · 2 yr ago
Team
58
US Form 5500 (plan participants) · Dec 2025 · -11% in a year
Grants
$78.5M
61 grants · CORDIS
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 3, 2025 Launched EpiCypher Launches Fiber-seq, a Breakthrough Multiomic Single-Molecule Genomics Assay · epicypher.com Sep 3, 2025 Partnership PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow · Nasdaq Jun 27, 2024 Raised a round Venture round $3.3M · SEC Form D Jan 23, 2024 Partnership AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays · PRNewswire 2012 Founded
Funding rounds
RoundDateAmountInvestorsSource
Grant Sep 2025 $1.2M — CORDIS
Grant Sep 2025 $1.3M — CORDIS
Grant Aug 2025 $1M — CORDIS
Grant Sep 2024 $2.5M — CORDIS
Grant Sep 2024 $2M — CORDIS
Grant Aug 2024 $2.5M — CORDIS
Venture round Jun 2024 $3.3M — SEC Form D
Grant Mar 2024 $2.5M — CORDIS
Grant Sep 2023 $2.5M — CORDIS
Grant Jul 2023 $3M — CORDIS
Grant Jul 2023 $406k — CORDIS
Grant Jun 2023 $2.6M — CORDIS
Grant May 2023 $406k — CORDIS
Grant Mar 2023 $3M — CORDIS
Grant Feb 2023 $2.3M — CORDIS
Grant Sep 2022 $327k — CORDIS
Grant Sep 2022 $500k — CORDIS
Grant Sep 2022 $406k — CORDIS
Grant Sep 2022 $2M — CORDIS
Grant Aug 2022 $3M — CORDIS
Grant Jun 2022 $2M — CORDIS
Grant May 2022 $2.1M — CORDIS
Grant Feb 2022 $530k — CORDIS
Grant Jan 2022 $2M — CORDIS
Grant Sep 2021 $302k — CORDIS
Grant Sep 2021 $2M — CORDIS
Grant Sep 2021 $2M — CORDIS
Grant Jul 2021 $307k — CORDIS
Grant May 2021 $3M — CORDIS
Grant Apr 2021 $2M — CORDIS
Grant Sep 2020 $2M — CORDIS
Grant Sep 2020 $397k — CORDIS
Grant Feb 2020 $2.9M — CORDIS
Grant Feb 2020 $1.8M — CORDIS
Grant Dec 2019 $1.8M — CORDIS
Grant Sep 2019 $259k — CORDIS
Grant Aug 2019 $300k — CORDIS
Grant Aug 2019 $2M — CORDIS
Grant Jun 2019 $285k — CORDIS
Grant Jun 2019 $300k — CORDIS
Grant Jan 2019 $300k — CORDIS
Grant Sep 2018 $2M — CORDIS
Grant Sep 2018 $300k — CORDIS
Grant Sep 2018 $285k — CORDIS
Grant Aug 2018 $300k — CORDIS
Grant Jun 2018 $300k — CORDIS
Grant Jun 2018 $1.7M — CORDIS
Grant Mar 2018 $2.1M — CORDIS
Grant Mar 2018 $300k — CORDIS
Grant Feb 2018 $300k — CORDIS
Grant Feb 2018 $1.7M — CORDIS
Grant Sep 2017 $1.6M — CORDIS
Grant Aug 2017 $1.5M — CORDIS
Grant Aug 2017 $225k — CORDIS
Grant Jun 2017 $225k — CORDIS
Grant Mar 2017 $225k — CORDIS
Grant Sep 2016 $225k — CORDIS
Grant Sep 2016 $224k — CORDIS
Grant Sep 2016 $224k — CORDIS
Grant Jul 2016 $224k — CORDIS
Grant Mar 2016 $225k — CORDIS
Grant Dec 2015 $1.6M — CORDIS
Registers and programsofficial lists and records that name the company
Legal entity EPICYPHER, INC. SEC Form D
Founders and leadersfrom filings, registers and the company's site
James BoneExecutive Officer, DirectorSEC Form D

Visa sponsorship

  • United States · Filed H-1B visas in the last two years

Visa details by country

Overview

As your research partner, EpiCypher provides cutting-edge tools and services for epigenetics and chromatin biology research.

News

Blog 4 months ago
CUT&RUN Decodes Drug Resistance Mechanisms
Beyond RNA-seq: Applying CUT&RUN to Decode Drug Resistance and Inform Rational Combination Therapies Key Takeaways:RNA-seq and ATAC-seq reveal transcriptional rewiring associated with cancer drug resistance; however, they only indirectly implicate the res
Read more
Report
Press release PRNewswire 5 months ago
EpiCypher and New England Biolabs Expand Strategic Partnership to Advance Epigenomics Research
/PRNewswire/ -- EpiCypher and New England Biolabs (NEB) today announced an expanded strategic partnership to co-develop next-generation tools for...
Read more
Report
Blog 5 months ago
Fiber-seq Applied to Brain Cells Enhances Neuro Research
Fiber-seq Provides a More Complete View of the Human Brain Epigenome Fiber-seq: A Solution to Uncover Unmapped Epigenomic RegionsChromatin profiling assays employed to detect accessible chromatin regions represent a widely used means of generating genome-
Read more
Report
Blog 7 months ago
Tracing the H3K36me2 Signal: CUT&RUN Enabled Insights into NSD2 Inhibitor Response
Interrupting the epigenetic programs that drive tumor growth is a promising avenue for cancer therapy, and NSD2 is emerging as a compelling target. However, robust technologies are needed to define the mechanism of action of NSD2-targeted therapeutics, pa
Read more
Report
Blog 8 months ago
Placing CUT&RUN Data Analysis Back in the Hands of Biologists
CUT&RUN and CUT&Tag have become gold-standard methods for profiling protein-DNA interactions, offering high resolution, low background, and efficient sequencing. While these assays dramatically simplified experimental workflows, data analysis has remained
Read more
Report
Blog 11 months ago
Redefining High-Resolution DNA Methylation Mapping
Durham, NC - Oct. 16, 2025 (The Scientist) - Winning a spot in the 2025 Top Innovations contest's Lab Research Tools category, the CUTANA meCUT&RUN kit harnesses engineered proteins to capture DNA methylation sites at scale.DNA methylation is an epigeneti
Read more
Report
Blog 11 months ago
Headed to SfN? 4 Ways CUT&RUN and CUT&Tag Are Advancing Neuroscience
Epigenetic mechanisms shape nearly every aspect of neurobiology-from guiding early neural development to regulating plasticity, cognition, and responses to injury or disease. Interest in chromatin profiling in neuroscience continues to grow, as researcher
Read more
Report
Blog 12 months ago
Major Updates to CUTANA CUT&Tag Kits: Improved Performance at Lower Costs
Funding challenges are a reality for many researchers, and we want to make sure innovation doesn't slow down because of it. That's why our team has introduced major updates to CUTANA CUT&Tag assays - making them more streamlined, affordable, and accessibl
Read more
Report
Blog 12 months ago
Fiber-seq 101: A Multiomic Assay That Goes Beyond ATAC-seq
How do cells control when and where genes are expressed? The answer lies in a complex interplay of regulatory proteins that govern chromatin accessibility and architecture. These processes establish cell identity and maintain genome stability, and when di
Read more
Report
News Nature 1 year ago
Multivalent binding of the tardigrade Dsup protein to chromatin promotes yeast survival and longevity upon exposure to oxidative damage
Tardigrades are remarkable in their ability to survive extreme environments. The damage suppressor (Dsup) protein is thought to contribute to their extreme resistance to reactive oxygen species (ROS) generated by irradiation. Here we show that expression
Read more
Report
Show more news

People

James Bone
Executive Officer, Director
Mark Bedford
Director
Or Gozani
Director
Michael-Christopher Keogh
Director
Andrew Barry
Director
Joe McMahon
Director
Brian Strahl
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
3
Hiring now
0
Countries
1
Loading the map
Headquarters Builds here Office with open vacancies No open vacancies right now Tap a pin for the office
Durham United States
HQ
Cambridge United States
Regional office
United Kingdom - Cambridge Bioscience
company site
Belgium United States
Regional office
Belgium & Luxembourg - Tebubio
company site

Financials

Total raised
$81.8M
Latest round
Grant
Funding rounds
62
Funding rounds
Round Announced Amount
Grant 2025 $1.2M Details
Grant 2025 $1.3M Details
Grant 2025 $1M Details
Grant 2024 $2.5M Details
Grant 2024 $2M Details
Grant 2024 $2.5M Details
Venture - Series Unknown 2024 $3.3M Details
Grant 2024 $2.5M Details
Grant 2023 $2.5M Details
Grant 2023 $3M Details
Grant 2023 $406k Details
Grant 2023 $2.6M Details
Grant 2023 $406k Details
Grant 2023 $3M Details
Grant 2023 $2.3M Details
Grant 2022 $327k Details
Grant 2022 $500k Details
Grant 2022 $406k Details
Grant 2022 $2M Details
Grant 2022 $3M Details
Grant 2022 $2M Details
Grant 2022 $2.1M Details
Grant 2022 $530k Details
Grant 2022 $2M Details
Grant 2021 $302k Details
Grant 2021 $2M Details
Grant 2021 $2M Details
Grant 2021 $307k Details
Grant 2021 $3M Details
Grant 2021 $2M Details
Grant 2020 $2M Details
Grant 2020 $397k Details
Grant 2020 $2.9M Details
Grant 2020 $1.8M Details
Grant 2019 $1.8M Details
Grant 2019 $259k Details
Grant 2019 $300k Details
Grant 2019 $2M Details
Grant 2019 $285k Details
Grant 2019 $300k Details
Grant 2019 $300k Details
Grant 2018 $2M Details
Grant 2018 $300k Details
Grant 2018 $285k Details
Grant 2018 $300k Details
Grant 2018 $300k Details
Grant 2018 $1.7M Details
Grant 2018 $2.1M Details
Grant 2018 $300k Details
Grant 2018 $300k Details
Grant 2018 $1.7M Details
Grant 2017 $1.6M Details
Grant 2017 $1.5M Details
Grant 2017 $225k Details
Grant 2017 $225k Details
Grant 2017 $225k Details
Grant 2016 $225k Details
Grant 2016 $224k Details
Grant 2016 $224k Details
Grant 2016 $224k Details
Grant 2016 $225k Details
Grant 2015 $1.6M Details